New York, USA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Global Vaccine Contract Manufacturing Market to Boost with a Significant ~7% CAGR by 2032 | DelveInsight The vaccine contract manufacturing market ...

This activity saw the managers exit Lonza (due to the Moderna contract termination and related capital misallocation, and underperformance of its US vitamins business), Nike (strategic pivot to ...

Moderna first announced it would scale down manufacturing of its Spikevax COVID-19 vaccine in late 2023, including at contract drug manufacturer Lonza's facility in Switzerland, as part of an effort ...

Valencian A Spanish pharmaceutical firm will become only the second European company to make the ingredients for Moderna’s coronavirus vaccine. Rovi will join Swiss firm Lonza To contact the ...

Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

Joana Correia, Co-Founder and CEO, Exogenus Therapeutics, commented, “This collaboration with Lonza will be essential to ...

As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top ...

Lonza will leverage its expertise in exosome development and analytical services to define a GMP-compliant process for Exo-101 production.

The Pease Development Authority’s Board of Directors voted to approve the concept plan for Lonza Biologics Inc., to install “canopy sunshades." ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...